BioAssay Works (Maryland, USA) develops lateral-flow, point-of-care and point-of-use diagnostic tests, with emphasis on assays requiring high sensitivity. The company has patented enabling technologies, including a lateral-flow platform, and proprietary gold-sol manufacturing methods which contribute to increased test sensitivity and specificity, and which reduce response time. BAW’s founders have extensive experience in developing FDA-approved, CE mark, and USDA-regulated ELISA and rapid tests.
The company has become the assay-development partner-of-choice for many established players in the rapid-assay industry. Based on the demonstrable superiority of tests developed by BioAssay Works, the company’s scientists have earned a world-class reputation.